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Young Adult Female Cancer Survivors’ Concerns
About Future Children’s Health and Genetic Risk
Nirupa Jaya Raghunathan, MD,1,2 Catherine Benedict, PhD,3 Bridgette Thom, MS,1,2
Danielle Novetsky Friedman, MD, MS,2,4 and Joanne Frankel Kelvin, MSN, RN, AOCN,1,2

As young adult female cancer survivors (aged 18–35) make family-building decisions, understanding the
specific nature of their concerns is important. We evaluated survivors’ concerns about potential health risks to
future children including genetic susceptibility for cancer with an internet-based survey study (N = 187). Sixtyfive percent reported concern about passing on a genetic cancer risk to their children, and scores did not vary
regardless of association with cancer at high risk for genetic transmission. Genetic counseling and education
about family-building options may be important to survivors concerned about health risks to offspring to
support family-building decisions based on personalized medical information.
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Introduction

C

oncerns about cancer-related fertility and future
family-building are multifaceted and can include fears
about how a cancer diagnosis or treatment will affect future
children’s health.1 This concern may be particularly relevant
to young adult female cancer survivors (YAFCSs), currently
aged 18–35 years who were treated at anytime in the past, as
they are likely to have been diagnosed before starting or
completing their desired childbearing.2 As providers discuss
options to preserve fertility before treatment through oocyte,
embryo, or ovarian tissue cryopreservation, and provide
guidance on post-treatment family building, consideration of
the patient’s understanding of the consequences of cancer and
cancer therapy on offspring becomes even more germane.3
There is no medical evidence that cancer therapies present a
risk for congenital abnormalities in offspring4 and, in the absence of a hereditary cancer syndrome, there is no increased
incidence of genetic disease in offspring of cancer survivors.5
Studies have described adverse pregnancy outcomes in
childhood cancer survivors noting increased rates of prematurity, low birth weight, and miscarriage, specifically where
treatment involved abdominal radiation.6 Few studies have
evaluated YAFCSs’ concerns about cancer-related health risks
to offspring and genetic risk heritability. Estimates suggest that
14%–35% of young patients believe their cancer treatment
could cause health problems for future children, with another
37% unsure of health risks.7,8 Some evidence points to a lack
of knowledge or confusion about treatment effects (e.g., fears

of ‘‘defective genes’’ due to radiation exposure) as a source of
fears related to genetic inheritance.9 Survivors of adolescent
cancer have expressed an imagined feeling of responsibility
regarding the potential health problems of future children with
some reporting a decreased desire for children due to this
concern.10 Notably, worries may persist despite receiving information from clinicians that concern about genetic risk
heritability from cancer treatment was unfounded.10
Although there is an emerging body of literature suggesting
that infertility is among the more distressing survivorship topics
for YAFCSs,11 it is unclear how concerns about future offspring’s health contribute to this distress. The field of genetic
counseling has shown that patients’ subjective estimate of
cancer risk tends to be higher than actual risk, but is reduced
with the receipt of targeted, individualized counseling.12 A first
step in developing fertility counseling resources for YAFCSs is
to better understand the nature of their concerns and identify
those who may be at higher risk for misinformation. This study
describes YAFCSs’ concerns about the health of future children
and perceptions of genetic risk after exposure to gonadotoxic
cancer therapy. Specifically, we sought to evaluate whether
concerns varied based on demographic or clinical factors and
across disease subgroups based on disease heritability.
Methods
Design

Fertility-related perceptions of YAFCSs who had
completed therapy were assessed using a cross-sectional
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internet-based survey.13 This secondary analysis focused on
concerns related to the health of future children specifically.
Surveys were administered between February and March 2015.
This study was approved by the Memorial Sloan Kettering Cancer
Center (MSK) Institutional Review Board/Privacy Board.
The survey was designed by an interdisciplinary team and
incorporated feedback from YAFCSs. The survey was anonymous, and protected health information was not collected.
Standard questions assessed sociodemographic, medical, and
fertility-related information as reported by the patient. The survey was administered online using a commercially available
website with secure sockets layer encryption. Participants were
recruited through MSK and 17 young adult cancer survivor advocacy groups using social media and email listservs. These
procedures are consistent with recommended use of social media
in young adult oncology research14–16 and similar to previously
published studies with this population.17,18 Respondents were
required to answer screening items to confirm eligibility.
Participants

Eligibility criteria included female cancer survivors 18–35
years old, who had completed treatment and were disease
free. This secondary analysis excluded respondents who reported they did not desire future children or who had been
told they were infertile or unable to carry a pregnancy.
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respondents who expressed a desire for future children had
not been previously told they were infertile, and those who
completed the entire CHS were included in this analysis, with
a final sample of 187 (Table 1). Only 29 participants (8.4%)
who met initial eligibility criteria reported that they ‘‘definitely did not’’ want (more) children in the future and were
excluded from analyses. There were no differences in demographic or clinical characteristics between the subgroup analyzed in this report and the other respondents in the sample
( p > 0.05). Within this subgroup, average age at the start of
treatment was 23.7 years (standard deviation [SD] = 7.2, range
0–34), and mean current age was 29.5 years (SD = 4.1, range
18–35). Respondents were on average 4.4 years (SD = 4.9,
range = 0–26) from treatment completion. The most common
cancer diagnoses were lymphoma, breast, leukemia, ovarian,

Table 1. Sociodemographic and Clinical Data
of the Study Sample of Young Adult Female
Cancer Survivors (n = 187) Who Completed
the Child’s Health Subscale

Age at diagnosis (years)
Age at survey completion (years)
Duration of survivorship (years)

Measures

The 3-item Child’s Health Subscale (CHS) is a subset of the
18-item, validated Reproductive Concerns after Cancer Scale
(RCACS). The other five subscales in the RCACS include
(three items each) Fertility Potential, Partner Disclosure, Personal Health, Acceptance (reverse coded), and Becoming
Pregnant.1 The CHS consists of three questions: (1) I am
worried about passing on a genetic risk for cancer to my
children, (2) I am worried how my family history might affect
my children’s health, and (3) I am afraid my children would
have a high chance of getting cancer. Each question was
evaluated individually. Participants responded on a five-point
Likert scale from ‘‘Strongly disagree’’ to ‘‘Strongly agree.’’
The subscale score ranges from 3 to 15. Higher scores indicate
greater reproductive concerns (Cronbach’s alpha = 0.83).
Data analysis

Secondary analyses were conducted on participants with
complete data on the CHS. Descriptive statistics characterized
subscale responses and sociodemographic and clinical data.
Independent t-tests compared subscale responses by sociodemographic/clinical groups. Group comparisons included
race, education level, and cancer diagnoses. Diagnoses were
differentiated between those with and those without a strong
family history component (breast, colorectal, and ovarian vs.
all other cancer types), as identified in National Comprehensive Cancer Network guidelines for adolescent and young
adult oncology.2 Pearson’s correlation assessed the relationship between age and subscale responses.
Results

Seven hundred fourteen YAFCSs accessed the survey,
with 359 meeting initial eligibility screening criteria. Of eligible respondents, 346 completed the survey in its entirety;

Total
<15 years of age at diagnosis
Race
White
Other
No response
Hispanic ethnicity
Education
<College degree
qCollege degree
Enrolled student (full or part time)
Employed (full or part time)
Annual household income
Had at least one child
Diagnosisa
Lymphoma
Breast
Other
Leukemia
Ovarian
Colorectal
Sarcoma
Brain
Cervical
Uterine
Lung
Genetic risk diagnosis
Treatmenta
Surgery
Chemotherapy
Radiation
Bone marrow transplant
a
Not mutually exclusive.
SD, standard deviation.

M (SD)

Range

23.7 (7.2)
29.5 (4.1)
4.4 (4.9)
n
183
20

0–34
18–35
0–26
%
100
11

162
18
3
14

89
10
2
8

40
143
43
149

22
78
24
80

50

27

54
41
29
15
14
13
11
5
2
2
1
68

29
22
16
8
7
7
6
3
1
1
1
36

4
155
14
6

2
83
8
3
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FIG. 1. Young adult female
cancer survivors’ responses to the
Child’s Health Subscale, depicting
concern about heritable health risk.

and colorectal. Most participants were married or living with a
partner (62%), earned a college degree or higher (78%), and
were employed full or part time (80%).
The mean total CHS score was 11.3 (SD = 3.3, range 3–15).
As noted in Figure 1, at the item level, 65% of YAFCSs were
worried about passing on a genetic risk for cancer to offspring,
with 34% of respondents indicating the highest level of
agreement by responding strongly agree. Sixty-two percent
were afraid that their children would have a high chance of
getting cancer, with 27% strongly agreeing. Seventy-two
percent were worried about how their family history would
affect their children’s health, with 38% strongly agreeing.
The CHS scores were not correlated with age at diagnosis
or age at time of survey nor did they vary by marital status,
race, prior children, or education level (Table 2). Diagnoses
were divided into two categories based on how likely the
disease is to be associated with a transmissible genetic mutation (actual data about each respondent’s genetic status were
not available). When comparing CHS scores between patients
with diagnoses most likely to be associated with a transmissible genetic mutation (breast, ovarian, and colorectal cancer)
(mean = 11.2, SD = 3.4) and all other diagnoses (mean = 11.3,
SD = 3.2), there was no variation (t = 0.28, df = 185, p = 0.78).
In both groups of patients, 65% of YAFCSs expressed concern

related to genetic risk for cancer in offspring, suggesting the
possibility of an inappropriate or unnecessary concern among
those respondents who did not have a heritable diagnosis.
Discussion

We previously reported that YAFCSs have substantial unmet information and support needs related to fertility and
family building post-treatment.13 This analysis was conducted
to better understand a particular aspect of reproductive concern

Table 2. Results of Bivariate Statistics
for Child’s Health Subscale Scores
Variable
Race
Education
Marital status
Prior children
Genetic risk diagnosis
Age at diagnosis
Age at survey

Mean Standard
difference error
0.41
0.13
0.08
0.76
0.14

0.80
0.59
0.51
0.65
0.50

t/r

df

p

0.51
0.23
0.16
1.2
0.28
<0.01
0.01

178
181
185
185
185
—
—

0.61
0.82
0.87
0.25
0.78
0.99
0.87
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pertaining to concern about the health of future children. Our
findings are consistent with the limited available literature,10
as the majority of respondents noted concerns about future
children’s health: 65% worried about passing on a genetic
cancer risk, 62% were afraid children would have a high
chance of getting cancer, and 72% were worried how their
family history might affect their children’s health.
There were no differences in concern in our sample based on
the association of their cancer diagnoses with a transmissible
genetic mutation. These findings suggest there may be a subgroup of YAFCSs with inappropriate genetic risk concern (i.e.,
without substantiated medical evidence to suggest genetic
heritability) or a subgroup who are uninformed about their genetic risk profile. Inappropriate genetic concern may be related
to misinformation or mistaken beliefs regarding inheritance
patterns of their disease. Owing to the anonymous and selfreport nature of the study, it is unknown whether the respondents actually had a transmissible genetic mutation, what
genetic risk information they received, if any, in the course of
their cancer treatment, or whether they sought information from
other sources such as other healthcare providers, friends, family,
or websites. Understandably, a survivor may be fully aware of
the heritability status of her cancer and still be concerned or not.
Nevertheless, there are a number of reasons patients may
have misconceptions about the health of future children. They
may mistakenly believe that prior cancer treatment will cause
permanent genetic mutations in surviving oocytes, negatively
impacting the health of children conceived after treatment.19
The trend toward personalized medicine in cancer treatment,
such as genomic profiling for targeted therapy, also opens
opportunities for misunderstanding among patients. For example, patients have reported beliefs that genetic mutations
found in tumor cells are transmissible to future offspring.20
Increasing public awareness of genetic health risks, the growing popularity of commercially available germline testing, and
the high incidence (17.7%) of variants of unknown significance
further complicate discussions of hereditary risk.21,22 Research
shows ongoing difficulty in presenting these complex genomic
concepts to patients.23
There were several limitations to this study. Owing to
concerns about participant burden, more detailed information
about the reasons for YAFCSs’ concerns about children’s
health and genetic risk was not available. The survey was
anonymous, precluding validation of participant responses or
further comparison between eligible and ineligible patients.
Cancer diagnosis was based on self-report of disease type,
and individual heritable genetic risk profiles were unknown.
It is unknown whether participants answered the survey item
about family health history in reference to cancer genetic risk
exclusively or risks for other medical conditions. Participants
were recruited through social media and were a racially/
ethnically homogenous and relatively well-educated group,
which compromises the generalizability of the results. Assessment of genetic risk concern was limited to survivors’
consideration of future children. It is also true that survivors
may be concerned about children conceived before their diagnosis as well as risk related to pregnancy after treatment. It
may be important to tailor patient resources and genetic
counseling services to patient subgroups with varying informational and support needs. Future research is needed to
better understand YAFCSs’ knowledge and concerns about
genetic heritability and childbearing risks and to develop and
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assess counseling strategies around this specific fertility and
family-building topic in post-treatment survivorship.
When discussing survivorship care with YAFCSs, providers
should initiate discussions about family building plans. It may
be important that providers elicit YAFCSs’ concerns about the
health of future children and clarify misconceptions. If the
patient has a heritable syndrome, providers should make referrals for genetic counseling. For YAFCSs with an identified
heritable genetic mutation, such as BRCA1 or BRCA2,
counseling may include a discussion of preimplantation genetic diagnosis, which may alleviate some concern about
passing on genetic risks.24
Conclusion

Many YAFCSs have concerns about the health of future
children, particularly related to family history and passing on
a genetic risk for cancer. Future research should build on this
preliminary study with more comprehensive measures of
genetic concerns and in conjunction with valid medical information about genetic and other health risks to future
children. Educating patients about this aspect of reproductive
health, and tailoring information based on actual risk, or lack
of risk, may reduce distress about childbearing and facilitate
family-building decisions.
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